Bayer presents florbetaben Phase II data

Bayer AG (Xetra:BAY) said that in an open-label, international Phase II trial to diagnose Alzheimer's disease, florbetaben scans had >90% specificity and sensitivity of about 80%. The trial enrolled 8...